Quality management paradigm shift: Risk-centric practices come center stage
CDMOs have moved to risk-based quality management systems comprising highly integrated and digitalized processes powered by data to ensure drug quality.
Protein therapeutics to amp up outsourcing in animal health
With the boom in pet ownership and rising awareness about pet health, veterinary drug makers are betting big on protein therapeutics and outsourcing biologics development to CDMOs.
Establishing the simple complex: Route to a successful large molecule bioanalytical sample analysis
Learn the simple and complex connections that must be established for successful large molecule bioanalytical sample analysis supporting clinical trials.
Syngene Quality Control Biologics Lab
Our Quality Control Biologics lab uses the latest technology and equipment for testing biologics products, with a strong focus on digitalization and automation. Our stringent quality control procedures and standards ensure the accuracy and reliability of results. Further, we are one of the pioneers of real-wear-assisted reality glasses for collaborative technology transfer and hosting remote inspections in alignment with FDA guidelines.
How Syngene’s Green Chemistry initiatives reduced costs by 30% while increasing yield and reducing wastage
Learn how Syngene developed a robust and scalable Green GMP manufacturing process for an oncology drug compound in just eight weeks, which reduced costs by 30%.
CRDMO Syngene: Your partner in building a healthier world
With a 30-year history in biologics and pharmaceutical services, CRDMO Syngene is now primed to offer integrated drug discovery and development services across modalities. Discover why we are the preferred partner to more than 450 companies around the globe for drug substances, drug products, clinical development, and commercial manufacturing.
CROs at the high table of drug discovery
Find out how offshoring has reached an inflection point as CROs turn risk-sharing partners in discovery research.
CMOs bask in pill promise
With sponsors having more oral solid dosage (OSD) products in their pipelines, CMOs anticipate an increasing trend in OSD outsourcing. Find out the criteria to choose the right CMO for OSD outsourcing.
Pharma 4.0: Taking CDMO factories by storm
Contract development manufacturing firms are ramping up the adoption of Pharma 4.0 technologies as regulators and customers increasingly seek transparency and integrity in manufacturing data.
New modalities hog the limelight
Explore how Cell and Gene, mRNA, Bispecifics, and ADCs are turning the tide as CDMOs see service demand for these therapies soar.